adamantane has been researched along with Coronavirus Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cimolai, N | 1 |
| Grieb, P; Rejdak, K | 1 |
2 other study(ies) available for adamantane and Coronavirus Infections
| Article | Year |
|---|---|
Potentially repurposing adamantanes for COVID-19.
Topics: Adamantane; Betacoronavirus; China; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Cognitive Dysfunction; Coronavirus Infections; COVID-19; Dopamine Agents; Female; Humans; Male; Memantine; Middle Aged; Multiple Sclerosis; Pandemics; Parkinson Disease; Pneumonia, Viral; Protective Factors; SARS-CoV-2; Severity of Illness Index | 2020 |